Related Experiment Video
Updated: Nov 21, 2025
10:23
Sample Preparation for Endopeptidomic Analysis in Human Cerebrospinal Fluid
Published on: December 4, 2017
9.2K
Suprabasin-derived bioactive peptides identified by plasma peptidomics
Tomomi Taguchi1, Yoshio Kodera2,3, Kazuhito Oba1
1Department of Endocrinology, Diabetes and Metabolism, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa, 252-0374, Japan.
Scientific Reports
|January 14, 2021
Summary
Researchers developed a novel peptidomic strategy to discover low-abundance bioactive peptides in plasma. This method successfully identified three novel suprabasin-derived peptides with distinct biological functions and tissue distribution.
Area of Science:
- Biochemistry
- Proteomics
- Molecular Biology
Background:
- Identifying low-abundance, low-molecular-weight native peptides in plasma is challenging.
- Undiscovered bioactive or biomarker peptides may exist in plasma.
Purpose of the Study:
- To develop an efficient method for enriching and identifying low-molecular-weight native peptides in plasma.
- To discover novel bioactive peptides and characterize their functions.
Main Methods:
- Developed a method to remove high-abundance plasma proteins for peptide enrichment.
- Utilized mass spectrometry for comprehensive identification of native peptides.
- Chemically synthesized identified peptide sequences for functional analysis.
Main Results:
- Successfully identified three novel bioactive polypeptides derived from suprabasin.
- SBSN_HUMAN[279-295] suppressed appetite and increased locomotor activity.
- SBSN_HUMAN[225-237] and SBSN_HUMAN[243-259] stimulated proinflammatory cytokines via NF-κB signaling.
- These peptides were found in various human organs and expressed by macrophages.
Conclusions:
- The novel peptidomic strategy enables the discovery of previously unknown bioactive peptides in plasma.
- Suprabasin-derived peptides exhibit significant biological activities and diverse tissue distribution.
- This approach opens new avenues for biomarker and therapeutic peptide discovery.
